We forecast Q1 organic revenue growth of 4.7% YOY (in line with consensus), driven by Hearing Care (we forecast 4.9%) and Diagnostics (we forecast 8.4%), while Hearing Aids faces a tough YOY comparable (we forecast 3.6%). We expect 2024 to be back-end loaded and driven by Oticon Intent. We expect maintained 2024 guidance of 4–8% organic growth, c1% M&A growth, c-1% FX, and EBIT of DKK4.6bn–5.0bn. We reiterate our BUY and DKK400 target price.
We are slightly below consensus on Q1e LCY sales growth (we forecast 19.4%, consensus 21.4%) and LCY operating profit growth (we forecast 16.8%, consensus 19.5%), due to lower expected Wegovy sales. However, we believe the Ozempic US prescription trend will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.
We expect another strong quarter for European tablet sales in Q1, up c15% YOY, marking a third consecutive quarter with growth in the teens, which should help boost investor confidence (results due at 07:00 CET on 3 May). However, due to tough comparables for the legacy business and seasonality patterns, we expect the 2024 guidance to be maintained. We reiterate our BUY and have raised our target price to DKK145 (140).
We forecast Q1 organic sales growth of 3.0% YOY (consensus 2.8%) and an EBITA margin of 9.7% (consensus 9.6%). We see Hearing as starting well, and despite still-negative growth in Enterprise, we expect unchanged 2024 guidance. The upcoming CMD offers management scope to rebuild credibility, and we expect updated long-term targets to reflect “One-GN”. We reiterate our BUY and have raised our target price to DKK230 (215).
Embla Medical’s (formerly Össur’s) organic growth print in Q1 was solid, 7% above consensus of 5.6%. Reported margins were somewhat soft on unexpected one-offs related to cost saving initiatives, but underlying margins were in line with consensus, and the commentary from management about the gross-margin trajectory for the remainder of 2024 was supportive. On limited estimate changes, we reiterate our BUY and DKK39 target price.
We expect Embla Medical (formerly Ossur) to report another solid organic growth quarter, despite tough comparables and Easter effects. We forecast the bionics portfolio to continue to drive prosthetics growth, with more muted growth in Bracing and Support and Patient Care. While we expect the EBIT margin to expand YOY in Q1, and continue to build throughout 2024, we estimate previously taken cost savings to have less effect in the quarter. We reiterate our BUY and DKK39 target price.
We are slightly below consensus on Q1 LCY sales growth (we forecast 19.4%, consensus 20.1%) and LCY operating profit growth (we forecast 16.8%, consensus 17.3%), due to lower expected Wegovy sales. However, we believe the trend in Ozempic US prescriptions will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.
We forecast Q2 organic revenue growth of 7.6% YOY (in line with consensus), driven by the Chronic Care business segments, and an EBIT margin before special items of 27.6% (consensus 27.5%). We continue to expect QOQ improvements for the coming quarters. We expect the 2023/24 guidance to be unchanged for c8% organic revenue growth, and a 27–28% EBIT margin before special items. We reiterate our BUY, and have raised our target price to DKK1,050 (1,000).
Annual General Meeting 2024 – GN Store Nord A/S Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 19, 2024, as set out below. The report by the Board of Directors was noted by the general meeting. The Annual Report 2023 and the proposal on distribution of annual profits, including no distribution of dividends, were approved, and discharge was granted to the Board of Directors and the Executive Management. The general meeting approved the remuneration to the Board of Directors for 2024, ...
At its CMD, Demant updated its long-term outlook. It now targets 8–10% LCY growth (7–10%) including 6–8%-points organic growth and c2%-points M&A growth, and still sees incremental EBIT margin expansion. It expects the hearing-aid market to grow 4–6% p.a. in value (2–5%), as ASP is now guided fairly flat. We are positive on the Sirius-based Oticon Intent launch. We reiterate our BUY, and have raised our target price to DKK400 (375).
>Ostomy care - Strong growth in US to continue - While Coloplast is the strong global market leader with a share of c. 44% in ostomy care, the US represents a growth opportunity with a share in the high teens. We expect that the mixture ofsuccess at GPO contracts, major hospital groups as well as its approaches to increase awareness among patients and nurses directly, will lead to a marked improvement in traction over the next years. We forecast double-digit gr...
At its CMD, the company maintained its strategic aspirations for 2025. It also expects increasing operating profit margins in the coming years. A key focus was the phase I trial results for amycretin in obesity, showing 13.1% weight loss (no signs of plateau). While not confirmed, we still expect it to go directly to phase III development. We reiterate our BUY and have increased our target price to DKK1,100 (1,000) on higher pipeline valuation.
A director at Alk-Abello A S bought 1,880 shares at 132.600DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.